CD45RA-depleted T-cell therapy for EBV infections after allogeneic hematopoietic cell transplantation: a multicenter retrospective study
Journal for ImmunoTherapy of Cancer · 2026-11 · 14 (11) · e015599
DOI: 10.1136/jitc-2026-015599 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 16.11.2026. Verfasst von Chengjuan Luo und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Shanghai Children's Medical Center Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, Ch…. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Project of Disciplines of Excellence, Noncommunicable Chronic Diseases-National Science and Technology Major Project.
Abstract (Originalsprache)
Background
Survival outcomes for patients with Epstein-Barr virus (EBV) infection after allogeneic hematopoietic cell transplantation (allo-HCT) are poor when disease is refractory to rituximab, with or without chemotherapy, highlighting a clear need for alternative therapeutic strategies. Adoptive cellular therapy (ACT) has been explored as a means of providing memory T-cell support, but its therapeutic role in refractory EBV infection remains incompletely defined.
Methods
This retrospective multicenter study included 17 pediatric and adult allo-HCT recipients (age range, 7–66 years) with EBV infections refractory to ≥1 line of anti-EBV therapy who received CD45RA-depleted ACT.
Results
Of the 17 patients, 10 (58.82%) had EBV-associated post-transplant lymphoproliferative disorder. The first CD45RA-depleted T-cell infusion was administered at a median of 117 days (range, 50–696 days) after allo-HCT, at a cumulative dose of 20×10⁶ cells/kg (range, 8.09–51.13×10⁶ cells/kg), with a median of two infusion cycles (range, 1–6); four patients also received concurrent intrathecal ACT. 15 patients (88.24%) achieved an overall response. The median follow-up was 482 days (range, 44–933 days). The 90-day EBV DNA clearance rate was 82.35% (95% CI 48.18% to 94.97%). Treatment was well tolerated; emergent adverse events included acute graft-versus-host disease (GvHD) in two patients (11.76%), chronic GvHD in seven (41.18%), and primary disease relapse in one (5.88%). The 1-year overall survival rate was 76.47% (95% CI 48.83% to 90.45%).
Conclusion
CD45RA-depleted T-cell ACT provides clinical benefit in patients with EBV infection refractory to ≥1 line of anti-EBV therapy after allo-HCT, with a favorable safety profile in this cohort.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology and Oncology, Shanghai Children's Medical Center Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.
- GoBroad Medical Institute of Hematology (Shanghai Center), Liquan hospital, Shanghai, China.
- Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai,Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine,…
- Department of Hematology, The First People's Hospital of Yunnan Province, Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, China 694634285@qq.com wangxiaodong@scmc.com.cn hu_xiaoxia@…
- Department of Hematology and Oncology, Shanghai Children's Medical Center Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China 694634285@qq.com wangxiaodong@scmc.com.cn hu_xiaoxia@126.com.
- Collaborative Innovation Center of Hematology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Förderung
- National Natural Science Foundation of China
- Project of Disciplines of Excellence
- Noncommunicable Chronic Diseases-National Science and Technology Major Project
- Shanghai Hematology Clinical Specialty Capacity Enhancement Project
Zitieren
APA
Luo, C., Li, S., Jiang, C., Huang, J., Luo, Q., Liu, W., Wang, L., Zhang, Z., Lu, H., Chen, J., Zhu, H., Jin, C., Wang, Y., Wang, X., & Hu, X. (2026). CD45RA-depleted T-cell therapy for EBV infections after allogeneic hematopoietic cell transplantation: a multicenter retrospective study. Journal for ImmunoTherapy of Cancer, 14(11), e015599. https://doi.org/10.1136/jitc-2026-015599
Vancouver
Luo C, Li S, Jiang C, Huang J, Luo Q, Liu W, et al. CD45RA-depleted T-cell therapy for EBV infections after allogeneic hematopoietic cell transplantation: a multicenter retrospective study. Journal for ImmunoTherapy of Cancer. 2026;14(11):e015599. doi:10.1136/jitc-2026-015599
BibTeX
@article{Luo2026,
author = {Luo, Chengjuan and Li, Su and Jiang, Chuanhe and Huang, Jiayu and Luo, Qi and Liu, Wei and Wang, Luxiang and Zhang, Zilu and Lu, Haiyang and Chen, Jing and Zhu, Hua and Jin, Chengwei and Wang, Yajie and Wang, Xiaodong and Hu, Xiaoxia},
title = {CD45RA-depleted T-cell therapy for EBV infections after allogeneic hematopoietic cell transplantation: a multicenter retrospective study},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2026},
volume = {14},
number = {11},
pages = {e015599},
doi = {10.1136/jitc-2026-015599}
}
EUVIMED